Robin David Isaacs new chief medical officer at Entasis Therapeutics
“Dr. Isaacs’ experience in clinical research, global clinical development and life-cycle management of infectious disease products is extremely valuable as we approach significant milestones with our lead candidate, ETX0914, and advance our preclinical pipeline,” Manos Perros, Ph.D., president and CEO of Entasis, said. “The expertise that Dr. Isaacs brings complements the strengths of our management team, enhancing our efforts to deliver novel cures to patients who lack other treatment options.”
Isaacs brings his vast experience as a pharmaceutical executive to the creation and launch of infectious disease products and vaccines.
“With significant milestones ahead and the opportunity to develop meaningful new treatments, this is an exciting time to be joining Entasis,” Isaacs said. “ETX0914, which is a first-in-class novel oral antibiotic currently in Phase 2 for the treatment of uncomplicated gonorrhea, has been designated a Qualified Infectious Disease Product (QIDP) by the FDA and awarded Fast-Track status. I am thrilled to be a part of a team exploring new therapies in a directed, focused way to introduce medicines with improved efficacy for these very challenging pathogens.”